| 7.16 0.01 (0.14%) | 09-17 15:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.39 | 1-year : | 9.8 |
| Resists | First : | 7.19 | Second : | 8.39 |
| Pivot price | 7.13  |
|||
| Supports | First : | 7.12 | Second : | 7.07 |
| MAs | MA(5) : | 7.14 |
MA(20) : | 7.12 |
| MA(100) : | 4.59 |
MA(250) : | 3.53 |
|
| MACD | MACD : | 0.3  |
Signal : | 0.4 |
| %K %D | K(14,3) : | 73.3 |
D(3) : | 62.2 |
| RSI | RSI(14): 84.3 | |||
| 52-week | High : | 7.19 | Low : | 1.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GTHX ] has closed below upper band by 20.1%. Bollinger Bands are 96% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.17 - 7.2 | 7.2 - 7.23 |
| Low: | 7.05 - 7.1 | 7.1 - 7.14 |
| Close: | 7.08 - 7.16 | 7.16 - 7.22 |
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Wed, 18 Sep 2024
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Stock Titan
Wed, 18 Sep 2024
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - GlobeNewswire
Thu, 05 Sep 2024
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - GlobeNewswire
Wed, 07 Aug 2024
Pharmacosmos Group to Acquire G1 Therapeutics - GlobeNewswire
Wed, 07 Aug 2024
Pharmacosmos to acquire G1 Therapeutics | Pharmaceutical | The Pharmaletter - The Pharma Letter
Mon, 24 Jun 2024
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 10.9 (%) |
| Held by Institutions | 54.2 (%) |
| Shares Short | 3,410 (K) |
| Shares Short P.Month | 5,770 (K) |
| EPS | -0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | -77 % |
| Operating Margin | -21.4 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | -109.1 % |
| Qtrly Rev. Growth | -61 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.1 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -8.32 |
| PEG Ratio | 0 |
| Price to Book value | 15.21 |
| Price to Sales | 6.48 |
| Price to Cash Flow | -10.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|